Is BPC-157 Legal in Louisiana? Federal Law, State Rules, and How to Get It

Where BPC-157 sits in FDA's lists

No FDA-approved drug contains BPC-157; FDA's July 2026 review found no approved product containing it in any country it searched [1]. FDA also noted that websites sell BPC-157 products as capsules, injections, oral sprays and nasal sprays, some labeled for research only; those products are not FDA-approved drugs [1]. Compounded drugs are not FDA-approved either: FDA does not review their safety, effectiveness or quality before marketing [3].

BPC-157 was in category 2, FDA's table of bulk substances that may present significant safety risks, from September 2023 until April 22, 2026. It then moved to the nominated-but-withdrawn table after the nominators withdrew [5][3]. Removal was not a finding of safety. FDA's page still carries its concern that compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration' [5].

On FDA's list of nominated bulk substances for state-licensed pharmacies and physicians, updated May 14, 2026, BPC-157 is in none of the three categories. FDA's category 1 policy therefore does not cover it [2]. It is also not on the list for outsourcing facilities [7].

The October 2026 HHS draft policy

On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for six peptides, scheduled for Federal Register publication on October 30, 2026 [4][3]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide, if the conditions are met [4][3]. For BPC-157 those conditions include:

• BPC-157 acetate only
• subcutaneous, intramuscular, oral or topical forms
• a single active ingredient
• a bulk substance from an FDA-registered manufacturer with a valid certificate of analysis
• a patient-specific prescription [3]

The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' [4].

FDA's own reviewers proposed that BPC-157 not be added to the pharmacy bulks list. Their reasons included that it is not well characterized chemically, that little is known about its safety and immunogenicity, and that evidence for ulcerative colitis, the use FDA evaluated, was insufficient [1]. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee nonetheless voted in favor of adding BPC-157 to the pharmacy bulks list, against the staff recommendation. The vote is advisory and non-binding. BPC-157 is not on the list, and adding it requires formal rulemaking [8][3].

Louisiana

The draft HHS policy names state-licensed pharmacies, federal facilities and licensed physicians without naming any state. A Louisiana pharmacy that met its conditions would therefore fall within the group the notice describes [3][4]. The policy is a draft and does not bind HHS. HHS may revisit it if a safety signal or product quality problem appears [4].

Safety and sport

FDA identified five small human studies, including a retrospective chart review and a 2-person intravenous pilot. It concluded there is 'insufficient clinical safety information to characterize the safety profile' [1]. A 2026 systematic review found 3 studies covering 30 patients, all of poor methodological quality and very low certainty [9]. WADA names BPC-157 in S0, prohibited at all times; the 2026 List has been in force since January 1, 2026 [6].